---
document_datetime: 2025-12-02 06:35:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/toviaz.html
document_name: toviaz.html
version: success
processing_time: 0.1113083
conversion_datetime: 2025-12-26 10:45:21.269649
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Toviaz

[RSS](/en/individual-human-medicine.xml/65644)

##### Authorised

This medicine is authorised for use in the European Union

fesoterodine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Toviaz. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Toviaz.

Expand section

Collapse section

## What is Toviaz?

Toviaz is a medicine containing the active substance fesoterodine. It is available as prolonged-release 4-mg tablets and 8-mg tablets. Prolonged-release means that fesoterodine is released slowly from the tablet over a few hours.

## What is Toviaz used for?

Toviaz is used in adults with overactive-bladder syndrome to treat the symptoms of the disease: increased urinary frequency (need to urinate frequently), urgency (sudden urge to pass urine), and urgency incontinence (sudden lack of control over urination).

The medicine can only be obtained with a prescription.

## How is Toviaz used?

The recommended starting dose of Toviaz is 4 mg once a day. The tablets are swallowed whole with a glass of water and must not be chewed. The patient normally gets the full effect of the treatment after two to eight weeks. Based upon individual response, the dose may be increased to 8 mg once daily.

The dose of Toviaz must be adjusted, or the medicine not used at all, in patients with problems with their kidneys or liver, depending on whether they are also receiving 'CYP3A4 inhibitors', a group of medicines that may affect the way Toviaz is broken down in the body. See the summary of product characteristics (also part of the EPAR) for full details.

## How does Toviaz work?

The active substance in Toviaz, fesoterodine, is an anticholinergic medicine. It blocks some receptors in the body, the muscarinic receptors. In the bladder, this causes the muscles that push urine out of the bladder to relax, leading to an increase in the capacity of the bladder and to changes in the way the bladder muscles contract as the bladder fills up. This helps Toviaz to prevent unwanted urination.

## How has Toviaz been studied?

The two main studies involved 1,964 patients with overactive-bladder syndrome and compared Toviaz (4 or 8 mg a day) with placebo (a dummy treatment). One of the studies also compared Toviaz with tolterodine (another medicine used in overactive-bladder syndrome). The main measure of effectiveness was the change in the number of times the patients needed to urinate in a 24-hour period after 12 weeks of treatment.

## What benefit has Toviaz shown during the studies?

Toviaz was more effective than placebo and as effective as tolterodine in reducing the number of times the patients urinated in a 24-hour period. Before treatment, patients needed to urinate about 12 times in 24 hours. This number was reduced by 1.74 and 1.86 with the 4-mg dose of Toviaz and by 1.94 with the 8-mg dose. The reductions seen in patients taking placebo and tolterodine were 1.02 and 1.69, respectively.

## What is the risk associated with Toviaz?

The most common side effect with Toviaz (seen in more than 1 patient in 10) is dry mouth. For the full list of all side effects reported with Toviaz, see the package leaflet.

Toviaz must not be used in people who are hypersensitive (allergic) to fesoterodine, to any of the other ingredients, to peanut or to soya. Toviaz must also not be used in patients with:

- urinary retention (difficulty in passing urine);
- gastric retention (when the stomach does not empty properly);
- uncontrolled narrow-angle glaucoma (increased eye pressure even with treatment);
- myasthenia gravis (a disease of the nerves causing muscle weakness);
- severe hepatic impairment (severe liver disease);
- severe ulcerative colitis (severe inflammation of the large intestine causing ulceration and bleeding);
- toxic megacolon (a very serious complication of colitis).

Toviaz must not be given to patients with moderate liver or moderate to severe kidney disease at the same time as strong CYP3A4 inhibitor medicines. These include medicines such as ketoconazole and itraconazole (used to treat fungal infections), atazanavir, indinavir, nelfinavir, ritonavir and saquinavir (medicines used in HIV-positive patients), clarithromycin and telithromycin (antibiotics), and nefazodone (used to treat depression).

## Why has Toviaz been approved?

The CHMP decided that Toviaz's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Toviaz

The European Commission granted a marketing authorisation valid throughout the European Union for Toviaz on 20 April 2007.

For more information about treatment with Toviaz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Toviaz : EPAR - Summary for the public

English (EN) (61.44 KB - PDF)

**First published:** 25/08/2009

**Last updated:** 14/09/2012

[View](/en/documents/overview/toviaz-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-293)

български (BG) (160.49 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/bg/documents/overview/toviaz-epar-summary-public_bg.pdf)

español (ES) (122.47 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/es/documents/overview/toviaz-epar-summary-public_es.pdf)

čeština (CS) (90.65 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/cs/documents/overview/toviaz-epar-summary-public_cs.pdf)

dansk (DA) (122.36 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/da/documents/overview/toviaz-epar-summary-public_da.pdf)

Deutsch (DE) (124.6 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/de/documents/overview/toviaz-epar-summary-public_de.pdf)

eesti keel (ET) (121.4 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/et/documents/overview/toviaz-epar-summary-public_et.pdf)

ελληνικά (EL) (162.42 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/el/documents/overview/toviaz-epar-summary-public_el.pdf)

français (FR) (124.77 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/fr/documents/overview/toviaz-epar-summary-public_fr.pdf)

italiano (IT) (124.91 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/it/documents/overview/toviaz-epar-summary-public_it.pdf)

latviešu valoda (LV) (90.09 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/lv/documents/overview/toviaz-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (147.29 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/lt/documents/overview/toviaz-epar-summary-public_lt.pdf)

magyar (HU) (144.23 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/hu/documents/overview/toviaz-epar-summary-public_hu.pdf)

Malti (MT) (89.99 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/mt/documents/overview/toviaz-epar-summary-public_mt.pdf)

Nederlands (NL) (121.93 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/nl/documents/overview/toviaz-epar-summary-public_nl.pdf)

polski (PL) (151.15 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/pl/documents/overview/toviaz-epar-summary-public_pl.pdf)

português (PT) (121.92 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/pt/documents/overview/toviaz-epar-summary-public_pt.pdf)

română (RO) (147.23 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/ro/documents/overview/toviaz-epar-summary-public_ro.pdf)

slovenčina (SK) (148.71 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/sk/documents/overview/toviaz-epar-summary-public_sk.pdf)

slovenščina (SL) (144.54 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/sl/documents/overview/toviaz-epar-summary-public_sl.pdf)

Suomi (FI) (123.18 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/fi/documents/overview/toviaz-epar-summary-public_fi.pdf)

svenska (SV) (115.2 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

14/09/2012

[View](/sv/documents/overview/toviaz-epar-summary-public_sv.pdf)

Toviaz : EPAR - Risk management plan

English (EN) (30.32 MB - PDF)

**First published:** 01/03/2024

[View](/en/documents/rmp-summary/toviaz-epar-risk-management-plan_en.pdf)

## Product information

Toviaz : EPAR - Product Information

English (EN) (372.71 KB - PDF)

**First published:** 25/08/2009

**Last updated:** 04/03/2025

[View](/en/documents/product-information/toviaz-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-818)

български (BG) (270.3 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/bg/documents/product-information/toviaz-epar-product-information_bg.pdf)

español (ES) (243.59 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/es/documents/product-information/toviaz-epar-product-information_es.pdf)

čeština (CS) (250.29 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/cs/documents/product-information/toviaz-epar-product-information_cs.pdf)

dansk (DA) (243.43 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/da/documents/product-information/toviaz-epar-product-information_da.pdf)

Deutsch (DE) (254.28 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/de/documents/product-information/toviaz-epar-product-information_de.pdf)

eesti keel (ET) (240.53 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/et/documents/product-information/toviaz-epar-product-information_et.pdf)

ελληνικά (EL) (275.02 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/el/documents/product-information/toviaz-epar-product-information_el.pdf)

français (FR) (248.65 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/fr/documents/product-information/toviaz-epar-product-information_fr.pdf)

hrvatski (HR) (254.02 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/hr/documents/product-information/toviaz-epar-product-information_hr.pdf)

íslenska (IS) (245.21 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/is/documents/product-information/toviaz-epar-product-information_is.pdf)

italiano (IT) (240.59 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/it/documents/product-information/toviaz-epar-product-information_it.pdf)

latviešu valoda (LV) (246.73 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/lv/documents/product-information/toviaz-epar-product-information_lv.pdf)

lietuvių kalba (LT) (240.58 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/lt/documents/product-information/toviaz-epar-product-information_lt.pdf)

magyar (HU) (250.96 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/hu/documents/product-information/toviaz-epar-product-information_hu.pdf)

Malti (MT) (277.71 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/mt/documents/product-information/toviaz-epar-product-information_mt.pdf)

Nederlands (NL) (248.46 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/nl/documents/product-information/toviaz-epar-product-information_nl.pdf)

norsk (NO) (234.1 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/no/documents/product-information/toviaz-epar-product-information_no.pdf)

polski (PL) (254.37 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/pl/documents/product-information/toviaz-epar-product-information_pl.pdf)

português (PT) (238.21 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/pt/documents/product-information/toviaz-epar-product-information_pt.pdf)

română (RO) (252.38 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/ro/documents/product-information/toviaz-epar-product-information_ro.pdf)

slovenčina (SK) (255.66 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/sk/documents/product-information/toviaz-epar-product-information_sk.pdf)

slovenščina (SL) (248.73 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/sl/documents/product-information/toviaz-epar-product-information_sl.pdf)

Suomi (FI) (240.61 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/fi/documents/product-information/toviaz-epar-product-information_fi.pdf)

svenska (SV) (239.83 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/03/2025

[View](/sv/documents/product-information/toviaz-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000256192 03/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Toviaz : EPAR - All Authorised presentations

English (EN) (26.09 KB - PDF)

**First published:** 05/12/2007

**Last updated:** 11/10/2012

[View](/en/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-789)

български (BG) (59.49 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/bg/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_bg.pdf)

español (ES) (15.54 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/es/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_es.pdf)

čeština (CS) (43.45 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/cs/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.96 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/da/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.74 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/de/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.49 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/et/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (55.57 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/el/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_el.pdf)

français (FR) (10.72 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/fr/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.97 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/hr/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.68 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/is/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_is.pdf)

italiano (IT) (15.05 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/it/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (44.39 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/lv/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (45.37 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/lt/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (45.06 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/hu/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (44.38 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/mt/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.42 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/nl/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.48 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/no/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_no.pdf)

polski (PL) (44.35 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/pl/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.16 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/pt/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_pt.pdf)

română (RO) (62.66 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/ro/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (45.42 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/sk/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.02 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/sl/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.55 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/fi/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (11.81 KB - PDF)

**First published:**

05/12/2007

**Last updated:**

11/10/2012

[View](/sv/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Toviaz Active substance fesoterodine fumarate International non-proprietary name (INN) or common name fesoterodine Therapeutic area (MeSH) Urinary Bladder, Overactive Anatomical therapeutic chemical (ATC) code G04BD11

### Pharmacotherapeutic group

Urologicals

### Therapeutic indication

Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.

## Authorisation details

EMA product number EMEA/H/C/000723 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Marketing authorisation issued 20/04/2007 Revision 30

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Toviaz : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (185.73 KB - PDF)

**First published:** 04/03/2025

[View](/en/documents/procedural-steps-after/toviaz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Toviaz : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (252.06 KB - PDF)

**First published:** 25/08/2009

**Last updated:** 04/03/2025

[View](/en/documents/procedural-steps-after/toviaz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Toviaz-H-C-723-II-0063 : EPAR - Assessment Report

Adopted

Reference Number: EMA/897876/2022

English (EN) (929.51 KB - PDF)

**First published:** 04/01/2023

[View](/en/documents/variation-report/toviaz-h-c-723-ii-0063-epar-assessment-report_en.pdf)

Toviaz-H-C-723-A46-030.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/261031/2021

English (EN) (1.04 MB - PDF)

**First published:** 25/05/2021

[View](/en/documents/variation-report/toviaz-h-c-723-a46-0301-epar-assessment-report_en.pdf)

Toviaz-H-C-723-A46-0025 : EPAR - Assessment Report

Adopted

Reference Number: EMA/819408/2012

English (EN) (629.81 KB - PDF)

**First published:** 20/12/2012

[View](/en/documents/variation-report/toviaz-h-c-723-a46-0025-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Toviaz : EPAR - Scientific Discussion

English (EN) (570.71 KB - PDF)

**First published:** 05/12/2007

**Last updated:** 05/12/2007

[View](/en/documents/scientific-discussion/toviaz-epar-scientific-discussion_en.pdf)

Toviaz : EPAR - Procedural steps taken before authorisation

English (EN) (21.05 KB - PDF)

**First published:** 05/12/2007

**Last updated:** 05/12/2007

[View](/en/documents/procedural-steps/toviaz-epar-procedural-steps-taken-authorisation_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/03/2025

## Share this page

[Back to top](#main-content)